

# HCC diagnostik: Radiologi

***Nikolaos Kartalis***

*MD, PhD, Associate professor*

*Department of Radiology Huddinge, Karolinska University Hospital*

*Division of Radiology, CLINTEC, Karolinska Institutet*

*Stockholm, Sweden*

*nikolaos.kartalis@ki.se*



**Karolinska  
Institutet**

**KAROLINSKA**  
Universitetssjukhuset

# Disclosures

- Institutional consultation and lecturing fees: Bayer, Guerbet, Ascelia Pharma, Icepharma, Servier Sweden, AstraZeneca
- Research grants: Siemens Healthineers



Karolinska  
Institutet

**KAROLINSKA**  
Universitetssjukhuset

# Upplägg



Karolinska  
Institutet

**KAROLINSKA**  
Universitetssjukhuset

- Hur gör vi?
- Utmaningar 
- Frågor
- Take-home

# Upplägg



Karolinska  
Institutet

**KAROLINSKA**  
Universitetssjukhuset


- ***Hur gör vi?***
- Utmaningar
- Frågor
- Take-home

Bilder tillhör  
Nikolaos Kartalis

# Mål

- Detektion
- Karakteristik
- Prognostisering
- Behandlingsplanering & respons

# EASL diagnostic algorithm and recall policy



**Fig. 2. Diagnostic algorithm and recall policy in cirrhotic liver.** \*Using extracellular MR contrast agents or gadobenate dimeglumine. \*\*Using the following diagnostic criteria: arterial phase hyperenhancement (APHE) and washout on the portal venous phase. \*\*\*Using the following diagnostic criteria: arterial phase hyperenhancement (APHE) and mild washout after 60 s. \*\*\*\*Lesion <1 cm stable for 12 months (three controls after four months) can be shifted back to regular six months surveillance. \*\*\*\*\*Optional for centre-based programmes.

**EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018**

# CT/MRI LI-RADS v2018





## CT/MRI Diagnostic Table

Arterial phase hyperenhancement (APHE)		No APHE		Nonrim APHE		
Observation size (mm)		< 20	≥ 20	< 10	10-19	≥ 20
Count additional major features: • Enhancing “capsule” • Nonperipheral “washout” • Threshold growth	None	LR-3	LR-3	LR-3	LR-3	LR-4
	One	LR-3	LR-4	LR-4	LR-4 LR-5	LR-5
	≥ Two	LR-4	LR-4	LR-4	LR-5	LR-5



Observations in this cell are categorized based on one additional major feature:

- LR-4 – if enhancing “capsule”
- LR-5 – if nonperipheral “washout” **OR** threshold growth



2015-10-13, 12:44:49

# CT portal venous ph




Bild-id: 145  
Image 145 of 188

2015-10-13, 12:44:49




Bild-id: 31  
Image 31 of 85

Bilder tillhör  
Nikolaos K...

2015-10-28, 08:45:29

### CT late arterial ph



Bild-id: 49  
Image 48 of 103

2015-10-28, 08:46:15

### CT portal venous ph



Bild-id: 45  
Image 44 of 103

2015-10-13, 12:44:49

### CT portal venous ph




Bild-id: 145  
Image 145 of 188

2015-10-28, 08:45:29




Bild-id: 36  
Image 36 of 100

2015-10-28, 08:47:30

### CT equilibrium ph




Bild-id: 42  
Image 41 of 103

2015-10-13, 12:44:49




Bild-id: 31  
Image 31 of 85





Bilder tillhör  
Nikolaos Kartalis




- Varför?


A. Vaskularitet

Bilder tillhör  
Nikolaos Kartalis

# Extracellulärt KM (DT + MR)

Bilder tillhör  
Nikolaos Kartalis





Extracellular space

Hepatocyte

Hepatocyte


Hepatocyte

Blood vessel

Bile duct

Extracellular space

Billroth's classification



Extracellular space

Hepatocyte

Hepatocyte


Hepatocyte

Blood vessel


Bile duct

Extracellular space

Billroth's classification



Billroth's classification



Extracellular space

Hepatocyte

Hepatocyte


Hepatocyte

Blood vessel

Bile duct


Extracellular space

Watermark: Bilimber.tumblr.com, Mikko Oja, Kari Kallio





Billroth's classification

Mikrogastras




Billroth's classification





Billroth's classification



Extracellular space

Hepatocyte

Hepatocyte


Hepatocyte

Blood vessel

Bile duct

Extracellular space

Billroth's classification






Image no: 64  
Image 49 of 112




Image no: 67  
Image 46 of 112




Image no: 66  
Image 47 of 112



Image no: 67  
Image 46 of 112



















Image no: 67  
Image 46 of 112





















Nikolaos Kartalis



• Varför?

A. Vaskularitet


B. Hepatobiliärfunktion


Bilder tillhör  
Nikolaos Kartalis

# Hepatobiliart KM (MR)

- Gadobenate dimeglumine  
Gd-BOPTA
- Gadoxetic acid  
Gd-EOB-DTPA

Bilder tillhör  
Nikolaos Kartalis





Extracellular space

Hepatocyte


Hepatocyte

Hepatocyte


Blood vessel

Bile duct

Extracellular space



Billroth's classification



Extracellular space

Hepatocyte

Hepatocyte


Hepatocyte

Blood vessel

Bile duct


Extracellular space

Biliverdin



Billroth's classification

Nikolaos Karalis



Extracellular space

Hepatocyte


Hepatocyte

Hepatocyte


Blood vessel

Bile duct

Extracellular space



Bilder tillhör Mikroskopias Kartais



Extracellular space

Hepatocyte


Hepatocyte

Hepatocyte

Blood vessel


Bile duct

Extracellular space




Billroth's classification

Mikrogastritis



Blindes Tumor-Karaktalis






Image no: 64  
Image 49 of 112




Image no: 67  
Image 46 of 112




Image no: 66  
Image 47 of 112




Image no: 67  
Image 46 of 112





Image no: 67  
Image 46 of 112

**MISSING**  
No image

# Teknik HBKM


Gadobenate dimeglumine

Gadoxetic acid



↑  
HB phase 1-2 h


↑  
HB phase 10-20 min




# Teknik HBKM

Gadobenate dimeglumine


Gadoxetic acid



T1-w, arterial ph




T1-w, arterial ph



T1-w, equilibrium ph



T1-w, transitional ph





• Varför?

- A. Vaskularitet
- B. Hepatobiliärfunktion
- C. Vätskeinhåll



• Varför?

- A. Vaskularitet
- B. Hepatobiliärfunktion
- C. Vätskeinhåll
- D. Cellularitet




• Varför?

- A. Vaskularitet
- B. Hepatobiliärfunktion
- C. Vätskeinhåll
- D. Cellularitet
- E. Fetinnehåll



• Varför?

- A. Vaskularitet
- B. Hepatobiliärfunktion
- C. Vätskeinhåll
- D. Cellularitet
- E. Fetinhåll




Bilder tillhör  
Nikolaos Kartalis



- Varför?

- A. Vaskularitet
- B. Hepatobiliärfunktion
- C. Vätskeinhåll
- D. Cellularitet
- E. Fetinhåll



- Mål

- Detektion
- Karakterisering
- Prognostisering
- Behandlingsplanering/respons

Bilder tillhör  
Nikolaos Kartalis



# Upplägg



Karolinska  
Institutet

**KAROLINSKA**  
Universitetssjukhuset

- Hur gör vi?
- ***Utmaningar***
- Frågor
- Take-home

Bilder tillhör  
Nikolaos Kartalis

# Utmaningar

- Teknik

Bilder tillhör  
Nikolaos Kartalis

2014-12-04, 08:42:23 CT arterial ph



Bild-id: 9  
Bild 8 av 44

2014-12-04, 08:42:17 CT portal venous ph



Bild-id: 9  
Bild 8 av 85

2014-12-04, 08:42:23




Bild-id: 34  
Bild 34 av 55

2014-12-04, 08:42:57



Bild-id: 30  
Bild 30 av 55

# EASL diagnostic algorithm and recall policy



**Fig. 2. Diagnostic algorithm and recall policy in cirrhotic liver.** \*Using extracellular MR contrast agents or gadobenate dimeglumine. \*\*Using the following diagnostic criteria: arterial phase hyperenhancement (APHE) and washout on the portal venous phase. \*\*\*Using the following diagnostic criteria: arterial phase hyperenhancement (APHE) and mild washout after 60 s. \*\*\*\*Lesion <1 cm stable for 12 months (three controls after four months) can be shifted back to regular six months surveillance. \*\*\*\*\*Optional for centre-based programmes.

**EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018**

2015-01-23, 09:28:01 CT arterial ph



Bild-id: 14  
Bild 13 av 134

2015-01-23, 09:28:18 CT portal venous ph



Bild-id: 10  
Bild 40 av 40

2015-01-23, 09:28:01



Bild-id: 58  
Bild 58 av 91

2015-01-23, 09:28:58




Bild-id: 35  
Bild 35 av 54

## Fråga

- Ser du några lesioner?
  - A. Nej, inga lesioner
  - B. En hypervasculär
  - C. En hypovasculär
  - D. Ingen aning...jag är kirurg!

”arterial ph”



portal venous ph



## Fråga

- Ser du några lesioner?
  - A. Nej, inga lesioner
  - B. En hypervasculär
  - C. En hypovasculär
  - D. Ingen aning...jag är kirurg!

arterial ph



"arterial ph"



portal venous ph



portal venous ph



## Fråga

- Ser du några lesioner?
  - A. Nej, inga lesioner
  - B. En hypervasculär**
  - C. En hypovasculär
  - D. Ingen aning...jag är kirurg!

arterial ph



"arterial ph"





portal venous ph




portal venous ph











Radiology. 2013 Feb;266(2):452-61. doi: 10.1148/radiol.12120826. Epub 2012 Nov 28.

## **Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.**

Davenport MS<sup>1</sup>, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK.





European Radiology (2020) 30:281–290  
<https://doi.org/10.1007/s00330-019-06358-7>

CONTRAST MEDIA



## Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice

Marie-Luise Kromrey<sup>1,2</sup> · Masatoshi Hori<sup>3</sup> · Satoshi Goshima<sup>4</sup> · Kazuto Kozaka<sup>5</sup> · Tomoko Hyodo<sup>6</sup> · Yuko Nakamura<sup>7</sup> · Akihiro Nishie<sup>8</sup> · Tsutomu Tamada<sup>9</sup> · Tatsuya Shimizu<sup>1</sup> · Akihiko Kanki<sup>9</sup> · Utaroh Motosugi<sup>1</sup> 




European Radiology (2020) 30:281–290  
<https://doi.org/10.1007/s00330-019-06358-7>

**CONTRAST MEDIA**

**Gadoxetate disodium-related  
 a prospective multi-institut**

Marie-Luise Kromrey<sup>1,2</sup> • Masatoshi Hori  
 Akihiro Nishie<sup>8</sup> • Tsutomu Tamada<sup>9</sup> • Ta


Eur Radiol (2020) 30:281–290



Breath hold pattern



Imaging artifact in arterial phase

■ G1 ■ G2 ■ G3 ■ G4



Bilder tillhör  
Nikolaos Kartalis


# Multiple arterial phases




Breath hold pattern

Imaging artifact in arterial phase

■ G1 ■ G2 ■ G3 ■ G4




Multiple arterial phases




Free-breathing




### Breath hold pattern




### Imaging artifact in arterial phase



## Multiple arterial phases




## Free-breathing





T1-w, unenhanced



T1-w, arterial ph



**Gadoxetic acid**

T1-w, portal venous ph

T1-w, 3 min






**Washout appearance??**

T1-w, unenhanced

T1-w, arterial ph

T1-w, unenhanced

T1-w, arterial ph



**Gadoxetic acid**



**EC KM**

T1-w, portal venous ph

T1-w, 3 min


T1-w, portal venous ph





T1-w, 3 min



**Washout appearance**

- Hemangioma
  - “Flash-filling”: pseudo-washout








# Utmaningar


- Teknik
- Låg sensitivitet för HCC

Bilder tillhör  
Nikolaos Kartalis

- 66 y.o.♀, HBV-cirrhosis
- FLL @ surveillance US




- 66 y.o.♀, HBV-cirrhosis
- FLL @ surveillance US




- 66 y.o.♀, HBV-cirrhosis




- 66 y.o.♀, HBV-cirrhosis
- TACE for 1:a HCC in dx liver lobe




- 66 y.o.♀, HBV-cirrhosis
- TACE for 2:a HCC in dx liver lobe



- 66 y.o.♀, HBV-cirrhosis
- TACE for 3:a HCC in dx liver lobe




- 66 y.o.♀, HBV-cirrhosis
- FLL @ surveillance US



Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoteric Acid-enhanced MRI: A Multicenter Study

≈65% HCC  
≈27% HG-DN  
≈8% LG-DN

- 66 y.o. S
- FLL @ S





# Utmaningar

- Teknik
- Låg sensitivitet HCC
- Prognostisering

- HCC mikrovaskulär invasion → recidiv

Bilder tillhör  
Nikolaos Kartalis

- HCC mikrovaskulär invasion → recidiv
- Transplantation

European Radiology  
<https://doi.org/10.1007/s00330-019-06424-0>

GASTROINTESTINAL

## Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation

Sunyoung Lee<sup>1,2</sup> • Kyoung Won Kim<sup>2</sup>  • Woo Kyoung Jeong<sup>3</sup> • Myeong-Jin Kim<sup>1</sup> • Gi Hong Choi<sup>4</sup> • Jin Sub Choi<sup>4</sup> • Gi-Won Song<sup>5</sup> • Sung-Gyu Lee<sup>5</sup>



- HCC mikrovaskulär invasion → recidiv
- Transplantation
- Resektion

European Radiology  
<https://doi.org/10.1007/s00330-019-06424-0>

GASTROINTESTINAL



## Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation

Sunyoung Lee<sup>1,2</sup> • Kyoung Won Kim<sup>2</sup>  • Woo Kyoung Jeong<sup>3</sup> • Myeong-Jin Kim<sup>1</sup> • Gi Hong Choi<sup>4</sup> • Jin Sub Choi<sup>4</sup> • Gi-Won Song<sup>5</sup> • Sung-Gyu Lee<sup>5</sup>

Research Article




 EASL | JOURNAL OF HEPATOLOGY


## Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma

Sunyoung Lee<sup>1</sup>, Seong Hyun Kim<sup>1,\*</sup>, Ji Eun Lee<sup>1</sup>, Dong Hyun Sinn<sup>2</sup>, Cheol Keun Park<sup>3</sup>

- HCC mikrovaskulär invasion → recidiv
- Transplantation
- Resektion



- HCC mikrovaskulär invasion → recidiv
- Transplantation
- Resektion





# Upplägg



Karolinska  
Institutet

KAROLINSKA  
Universitetssjukhuset

- Hur gör vi?
- Utmaningar
- **Frågor**
- Take-home

Bilder tillhör  
Nikolaos Kartalis

# Upplägg



Karolinska  
Institutet

**KAROLINSKA**  
Universitetssjukhuset

- Hur gör vi?
- Utmaningar
- Frågor
- ***Take-home***

# Take-home



Karolinska  
Institutet

**KAROLINSKA**  
Universitetssjukhuset

- Riktlinjer
- Teknik
- Levespicifika kontrastmedel
  - Sensitivitet
  - Prognostisering

Stort tack!

*nikolaos.kartalis@ki.se*



**Karolinska  
Institutet**

**KAROLINSKA**  
*Universitetssjukhuset*